AbbVie shares have fallen 4.4% since the company reported second-quarter 2026 results on July 31, even as revenues and earnings beat expectations and key drugs Skyrizi and Rinvoq posted robust growth. The decline came after AbbVie lowered its full-year 2026 adjusted EPS guidance to $13.87 to $14.07 from the prior range of $13.91 to $14.11, citing a roughly 14-cent impact from the pending $10.9 billion acquisition of Apogee Therapeutics, which is expected to close this quarter. The company raised its full-year revenue guidance by $300 million to $67.6 billion and said improved performance would offset about 10 cents of the deal's EPS drag. Combined Skyrizi and Rinvoq sales are expected to exceed $31 billion in 2026, with more than 20% growth, while the neuroscience portfolio, including new Parkinson's drug Vyalev, is also contributing to top-line gains. Despite the strong operational performance, near-term earnings estimates for 2026 have edged lower, and the stock currently carries a Zacks Rank #4 (Sell).
AbbVie IncLowered full-year EPS guidance due to Apogee acquisition despite strong Q2 results.
Apogee Therapeutics, Inc. Common StockPending acquisition by AbbVie expected to close this quarter, providing value to shareholders.
Johnson & Johnson
Eli Lilly and Company